280 related articles for article (PubMed ID: 24584736)
1. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Ezaz G; Long JB; Gross CP; Chen J
J Am Heart Assoc; 2014 Feb; 3(1):e000472. PubMed ID: 24584736
[TBL] [Abstract][Full Text] [Related]
2. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
3. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
4. Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.
Tsai HT; Isaacs C; Fu AZ; Warren JL; Freedman AN; Barac A; Huang CY; Potosky AL
Breast Cancer Res Treat; 2014 Feb; 144(1):163-70. PubMed ID: 24469642
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women: A Nationwide Cohort Study.
Chien HC; Kao Yang YH; Bai JP
JAMA Oncol; 2016 Oct; 2(10):1317-1325. PubMed ID: 27310478
[TBL] [Abstract][Full Text] [Related]
6. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
8. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis.
Wu WC; Huang CC; Tsai YF; Lin YS; Feng CJ; Chen YJ; Lai JI; Chao TC; Liu CY; Tseng LM
Breast Cancer Res Treat; 2023 Feb; 198(1):113-122. PubMed ID: 36586037
[TBL] [Abstract][Full Text] [Related]
9. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis.
Fogarassy G; Vathy-Fogarassy Á; Kenessey I; Kásler M; Forster T
Int J Cardiol; 2019 Jun; 285():47-52. PubMed ID: 30905520
[TBL] [Abstract][Full Text] [Related]
10. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-related cardiotoxicity among older patients with breast cancer.
Chavez-MacGregor M; Zhang N; Buchholz TA; Zhang Y; Niu J; Elting L; Smith BD; Hortobagyi GN; Giordano SH
J Clin Oncol; 2013 Nov; 31(33):4222-8. PubMed ID: 24127446
[TBL] [Abstract][Full Text] [Related]
13. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors.
Vo JB; Ramin C; Veiga LHS; Brandt C; Curtis RE; Bodelon C; Barac A; Roger VL; Feigelson HS; Buist DSM; Bowles EJA; Gierach GL; Berrington de González A
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38718210
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study.
Abdel-Qadir H; Tai F; Croxford R; Austin PC; Amir E; Calvillo-Argüelles O; Ross H; Lee DS; Thavendiranathan P
Circ Heart Fail; 2021 Jul; 14(7):e008110. PubMed ID: 34187164
[TBL] [Abstract][Full Text] [Related]
15. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.
Vaz-Luis I; Keating NL; Lin NU; Lii H; Winer EP; Freedman RA
J Clin Oncol; 2014 Mar; 32(9):927-34. PubMed ID: 24516021
[TBL] [Abstract][Full Text] [Related]
16. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
17. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
Jacobse JN; Schaapveld M; Boekel NB; Hooning MJ; Jager A; Baaijens MHA; Hauptmann M; Russell NS; Rutgers EJT; Aleman BMP; Sonke GS; van Leeuwen FE
Breast Cancer Res Treat; 2021 Jan; 185(1):205-214. PubMed ID: 32964358
[TBL] [Abstract][Full Text] [Related]
18. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database.
Kim YA; Cho H; Lee N; Jung SY; Sim SH; Park IH; Lee S; Lee ES; Kim HJ
Cancer Med; 2018 Dec; 7(12):6084-6092. PubMed ID: 30453386
[TBL] [Abstract][Full Text] [Related]
20. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
